CD8A and hepatocellular carcinoma: Here, we reported that higher CD8+ TCM proportion at baseline is associated with tumor inflammation in HCC, as well as with longer PFS in response to Atez/Bev treatment for HCC, especially in patients with an increase in CD8+ TEM cell proportion 3 weeks after treatment.